Previous 10 | Next 10 |
Results from new patient cohort, the largest to date, consistent with previously reported data Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its L...
Guardant Health liquid biopsy can help identify the 13 percent of patients harboring the KRAS G12C mutation, a previously undruggable target, who may be appropriate for LUMAKRAS Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA)...
Guardant Health (GH) has filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading statements Natera has made about its own products and performance of GH's new oncology test, Guardant Reveal. GH asked the federal cour...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading statements Natera has made about its own products and the performance of G...
With COVID-19 dominating the world's healthcare concerns for the past year and change, people have been letting a lot of other potential medical concerns slide. One result of that: a drop-off in cancer screenings. Even so, Guardant Health (NASDAQ: GH) -- a not insubstantial hold...
Guardant Health blood test identifies patients with EGFR exon 20 insertion mutations who may benefit from targeted treatment with RYBREVANT™ after progressing on or after platinum-based chemotherapy Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food a...
The FDA has approved Johnson & Johnson's (JNJ) Rybrevant (amivantamab-vmjw) as the first-ever treatment for patients with non small-cell lung cancer ("NSCLC") with a specific genetic mutation.The approval is for NSCLC tumors that express epidermal growth factor receptor ("EGFR") exon 20 i...
Buy Dexcom, Abiomed, and Eargo on the dip: William BlairDexCom (DXCM), Abiomed (ABMD), and Eargo (EAR) have underperformed in the year so far, but citing their quarterly reports, William Blair’s Margaret Kaczor thinks the group of med-tech stocks are attractive buys on the pullback.Des...
Guardant Health ([[GH]] +4.8%) listed 20 abstracts containing data to demonstrate the value of the company’s blood tests including LUNAR-2, Guardant Reveal, Guardant 360, and GuardantINFORM.The data from abstracts will be presented at the upcoming 2021 American Society of Cli...
Shares of Exact Sciences (NASDAQ: EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its Oncotype DX tests will be showcased at the upcoming American Society of Clinical Oncology (ASCO) annual meeting in June. However...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...